Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)
REACTOME PATHWAYThe Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) pathway (Reactome ID: R-HSA-5619110) involves 1 genes and is affected by 25 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.
Genes in this Pathway
Compounds Affecting Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)
| # | Compound | Targets Hit | Studies |
|---|---|---|---|
| 1 | Ritonavir | — | 298 |
| 2 | Atorvastatin | — | 1,000 |
| 3 | Simvastatin | — | 1,000 |
| 4 | Bilirubin | — | 296 |
| 5 | Pravastatin | — | 297 |
| 6 | Rifamycins | — | 300 |
| 7 | Rifamycins | — | 300 |
| 8 | Arachidonic Acid | — | 245 |
| 9 | Genistein | — | 300 |
| 10 | Losartan | — | 1,000 |
| 11 | Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). | — | 300 |
| 12 | beta Carotene | — | 299 |
| 13 | candesartan cilexetil [Supplementary Concept] | — | 300 |
| 14 | Gemfibrozil | — | 297 |
| 15 | Glyburide | — | 298 |
| 16 | Mometasone Furoate | — | 292 |
| 17 | Olmesartan Medoxomil | — | 300 |
| 18 | Thyroxine | — | 994 |
| 19 | Sirolimus | — | 300 |
| 20 | Antimycin | — | 300 |
| 21 | Digoxin | — | 299 |
| 22 | Silymarin | — | 10 |
| 23 | Taurocholic Acid | — | 300 |
| 24 | Thyroxine | — | 300 |
| 25 | Triiodothyronine | — | 300 |
About the Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) Pathway
The Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR) pathway is catalogued in Reactome (ID: R-HSA-5619110) and involves 1 genes. In the BiohacksAI corpus, 25 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include SLCO1B1.